Straits Times Index
3,377.65 +11.98 (+0.36%) S&P 500
4,076.60 +58.83 (+1.46%) Dow
34,086.04 +368.95 (+1.09%) Nasdaq
11,584.55 +190.74 (+1.67%) BTC-USD
23,098.62 +199.38 (+0.87%) CMC Crypto 200
523.36 +4.56 (+0.88%)
GILD May 2023 65.000 call
| Previous close | 23.99 |
| Open | 23.99 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 65.00 |
| Expiry date | 2023-05-19 |
| Day's range | 23.99 - 23.99 |
| Contract range | N/A |
| Volume | |
| Open interest | 152 |
- Zacks
Why Gilead (GILD) is Poised to Beat Earnings Estimates Again
Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Business Wire
Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
SANTA MONICA, Calif. & REDWOOD CITY, Calif., January 30, 2023--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, sa
- Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
FOSTER CITY, Calif., January 27, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
